Endocannabinoid system: An overview of its potential in current medical practice

Neuroendocrinology Letters

Volumn 30, Issue 2, 2009, Pages 153-179

  Mouslech, Zadalla ^a   Valla, Vasiliki ^b  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Abdominal obesity; Cannabinoids; Cardiometabolic risk; CB1 and CB2 receptors; Endocannabinoid system; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ACYLGLYCEROL LIPASE; ADIPONECTIN; ANANDAMIDE; ARACHIDONIC ACID; CANDESARTAN; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; DRONABINOL; ENDOCANNABINOID; FATTY ACID AMIDASE; FENOFIBRATE; GHRELIN; GLIMEPIRIDE; LOSARTAN; METFORMIN; NABILONE; NEBIVOLOL; NEUROTRANSMITTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; RETINOID X RECEPTOR; RIMONABANT; ROSIGLITAZONE; TARANABANT;

ALCOHOLISM; ANXIETY; BEHAVIOR; BONE METABOLISM; CARDIOVASCULAR FUNCTION; CELL PROLIFERATION; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DEPENDENCE; DRUG MECHANISM; DRUG SAFETY; ENERGY METABOLISM; ENZYME DEGRADATION; FERTILIZATION; FOOD INTAKE; GABAERGIC SYSTEM; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TRACT FUNCTION; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS; IMMUNE SYSTEM; LIVER DISEASE; MEDICAL PRACTICE; METABOLIC SYNDROME X; NAUSEA; NONHUMAN; OBESITY; ORGAN DISTRIBUTION; OSTEOLYSIS; PANCREAS ISLET; PATHOGENESIS; PREIMPLANTATION EMBRYO; PROTEIN BINDING; PROTEIN EXPRESSION; REPRODUCTIVE HEALTH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SPERMATOGENESIS;

EID: 70349309522     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (227)

1. Antuna-Puente B, Feve B, Fellahi S, Bastard JP (2008). Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 34(1): 2-11.
2. Ardawi MS, Rouzi AA (2005). Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 83(6): 1708-1716. (Pubitemid 40824803)
3. Ashton JC, Smith PF (2007). Cannabinoids and cardiovascular disease: the outlook for clinical treatments. Curr Vasc Pharmacol. 5(3): 175-185.
4. Astrup A, Christensen R, Bartels E, Bliddal H (2008). Efficacy and safety of the weight-loss drug rimonabant - Authors' reply. Lancet. 371(9612): 556-557. (Pubitemid 351232025)
5. Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008). Endocannabinoids and the Regulation of Bone Metabolism. J Neuroendocrinol. 20(Suppl 1): 69-74. (Pubitemid 351552679)
6. Bab I, Zimmer A (2008). Cannabinoid receptors and the regulation of bone metabolism. Br J Pharmacol. 153: 182-188.
7. Balen AH, Anderson RA (2007). Policy and practice of the BFS. Impact of obesity on female reproductive health: British Fertility Society, Policy and Practice Guidelines. Hum Fertil. 4: 195-206.
8. Bari M, Battista N, Fezza F, Gasperi V, Maccarrone M. 2006. New insights into endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem. 6(3): 257-268.
9. Basavarajappa BS (2007). Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett. 14(3): 237-246.
10. Batkai S, Pacher P, Osei-Hyiaman D, Radaeva S et al (2004). Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 110(14): 1996-2002. (Pubitemid 39331913)
11. Battista N, Bari M, Rapino C, Trassati F et al (2007). Regulation of female fertility by the endocannabinoid system. Hum Fertil. 10(4): 207-216. (Pubitemid 350215067)
12. Battista N, Rapino C, DiTommaso M, Pasquariello N et al (2008). Regulation of male fertility by the endocannabinoid system. Mol Cell Endocrinol. 286(1-2 Suppl 1): S17-S23.
13. Battista N., N. Pasquariello, M. Di Tommaso, M. Maccarrone (2008). Interplay Between Endocannabinoids, Steroids and Cytokines in the Control of Human Reproduction. J Neuroendocrinol. 20 (Suppl 1): 82-89. (Pubitemid 351552681)
14. Bellocchio L, Mancini G, Vicennati V, Paquali R et al (2006).Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol. 6(6): 586-591. (Pubitemid 44660950)
15. Bełtowski J, Jamroz-Wiśniewska A, Widomska S (2008). Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets. 8(1): 7-46.
16. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP et al (2003). The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 63(4): 908-914. (Pubitemid 36368998)
17. Bermundez-Silva FJ, Sanchez-Vera I, Suarez J, Serrano A et al (2007). Role of cannabinoid CB2 receptors in glucose homeostasis in rats. Eur J Pharmacol. 565(1-3): 207-211. (Pubitemid 46782769)
18. Bermundez-Silva FJ, Suarez J, Baixeras E, Cobo N et al. (2008). Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia. 51(3): 476-487.
19. Bifulco M, Malfitano A, Pisanti S, Laeazz C (2008). Endocannabinoids in endocrine and related tumours. Endocr Relat Cancer. 15(2): 391-408. (Pubitemid 351880830)
20. Bisogno T (2008). Endogenous Cannabinoids: Structure and Metabolism. J Neuroendocrinol. 20(1): 1-9.
21. Bluher M, Engeli S, Kloting N, Berndt J et al (2006). Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 55(11): 3053-3060. (Pubitemid 44923642)
22. Blüher M (2008). Efficacy and safety of the weight-loss drug rimonabant. Lancet. 371(9612): 555-556. (Pubitemid 351232024)
23. Blüher S, Mantzoros CS. 2007. Leptin in reproduction. Curr Opin Endocrinol Diabetes Obes. 14(6): 458-464.
24. Bouaboula M, Hilairet S, Marchand J, Fajas L et al. 2005. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol. 517(3): 174-181. (Pubitemid 40977892)
25. Brown AJ (2007). Novel cannabinoid receptors. Br J Pharmacol. 152(5): 567-575.
26. Budak E, Fernández Sánchez M, Bellver J, Cerveró A, Simon C, Pellicer A (2006). Interactions of the hormones leptin, ghrelin, adiponectin, resistin, and PYY3-36 with the reproductive system. Fertil Steril. 85(6): 1563-1581. (Pubitemid 43816423)
27. Burstein S (2005). PPAR-gamma: a nuclear receptor with affinity for cannabinoids. Life Sci. 77(14): 1674-1684.
28. Cabrai GA, Raborn ES, Griffin L, Dennis J, Marciano-Cabral F. (2008). CB2 receptors in the brain: role in central immune function. Br J Pharmacol. 153(2): 240-251.
29. Cacciola G, Chioccarelli T, Ricci G, Meccariello R et al (2008). The endocannabinoid system in vertebrate male reproduction: a comparative overview. Mol Cell Endocrinol. 286(1-2 Suppl 1): S24-S30.
30. Caminos JE, Tena-Sempere M, Gaytan F, Sanchez-Criado JE et al (2003). Expression of ghrelin in the cyclic and pregnant rat ovary. Endocrinology. 144(4): 1594-1602 (Pubitemid 36428502)
31. Capasso R, Matias I, Lutz B. Borrelli F et al (2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology. 129(3): 941-951. (Pubitemid 41242686)
32. Capasso R, Izzo A (2008). Gastrointestinal Regulation of Food Intake: General Aspects and Focus on Anandamide and Oleoylethanolamide. J Neuroendocrinol. 20(Supp1): 39-42. (Pubitemid 351552675)
33. Caraceni P, Domenicali M, Bernardi M (2008).The Endocannabinoid System and Liver Diseases. J Neuroendocrinol. 20(Supp1): 47-52. (Pubitemid 351552676)
34. Cobellis G, Cacciola G, Scarpa D, Meccariello R et al (2006). Endocannabinoid system in frog and rodent testis: type-1 cannabinoid receptor and fatty acid amide hydrolase activity in male germ cells. Biol Reprod. 75(1): 82-89. (Pubitemid 43946342)
35. Cota D, Marsciano G, Tschop M, Grubler Y et al. 2003. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 112(3): 423-431. (Pubitemid 38063771)
36. Cota D, Marsicano G, Lutz B, Vicennati V et al (2003). Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord. 27(3): 289-301.
37. Cota D, Tschop M, Horvath T, Levine A (2006).Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev. 51(1): 85-107. (Pubitemid 43782532)
38. Cota D (2007). CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev. 23: 507-517.
39. Cota D (2008). The Role of the Endocannabinoid System in the Regulation of Hypothalamic-Pituitary-Adrenal Axis. J Neuroendocrinol. 20(Suppl 1): 35-38.
40. Croci T, Landi M, Galzin AM, Marini P (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol. 140(1): 115-122. (Pubitemid 37175837)
41. Crown A, Clifton DK, Steiner RA (2007). Neuropeptide signaling in the integration of metabolism and reproduction. Neuroendocrinology. 86(3): 175-182. (Pubitemid 350073605)
42. Dennedy MC, Friel AM, Houlihan DD, Broderick VM et al (2004). Cannabinoids and the human uterus during pregnancy. Am J Obstet Gynecol. 190(1): 2-9.
43. DePetrocellis L, Marini P, Matias I, Moriello AS (2007). Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells. Exp Cell Res. 313(14): 2993-3004. (Pubitemid 47135571)
44. Despres J, Golay A, Sjostrom L (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 353(20): 2121-2134 (Pubitemid 41653104)
45. Despres J (2007). The endocannabinoid system. A new target for the regulation of energy balance and metabolism. Crit Pathways in Cardiol 6: 46-50. (Pubitemid 46878231)
46. Després JP (2007). The endocannabinoid system: a new target for the regulation of energy balance and metabolism. Crit Pathw Cardiol. 6(2): 46-50. (Pubitemid 46878231)
47. Després JP, Gaal LV, Pi-Sunyer X, Scheen A. 2008. Efficacy and safety of the weight-loss drug rimonabant. Lancet. 371(9612): 555. (Pubitemid 351232023)
48. Di Marzo V, Goparaju SK, Wang L, Batkai S et al (2001). Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410(6830): 822-825. (Pubitemid 32303781)
49. Di Marzo V, Bifulco M, De Petrocellis L (2004). The endocannabinoid system and its therapeutic exploitation. Nature Reviews, Drug Discovery. 3: 771-784. (Pubitemid 39242829)
50. Di Marzo V (2008). Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov. 7(5): 438-455.
51. Di Marzo V (2008). The endocannabinoid system in obesity and type 2 diabetes. Diabetologia DOI: 10.1007/s00125-008-1048-2.
52. DiCarlo C, Tommaselli GA, DiSpiezio A, Sammartino A et al (2007). Longitudinal evaluation of serum leptin and bone mineral density in early postmenopausal women. Menopause. 14(3 Pt 1): 450-454.
53. Elefteriou F (2008). Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys. 473(2): 231-236.
54. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K et al (2005). Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 54(10): 2838-2843. (Pubitemid 41401077)
55. Engeli S (2008). Dysregulation of the Endocannabinoid System in obesity. J Neuroendocrinol 20(Suppl 11): 110-115.
56. Fajardo G, Bernstein D (2007). Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity. J Am Coll Cardiol. 50(6): 537-539.
57. Ferré P. 2004. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 53(Suppl 1): S43-50. (Pubitemid 38168692)
58. Flygare J, Sander B (2008). The endocannabinoid system in cancer - Potential therapeutic target? Sem Cancer Biol. 18: 176-189.
59. Földy C, Neu A, Jones MV, Soltesz I (2006). Presynaptic, activity-dependent modulation of cannabinoid type 1 receptor-mediated inhibition of GABA release. J Neurosci. 26(5): 1465-1469. (Pubitemid 43237017)
60. Ford WR, Honan SA, White R, Hiley CR (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br J Pharmacol. 135(5): 1191-1198. (Pubitemid 34259120)
61. Fowler CJ (2007). The pharmacology of the cannabinoid system - a question of efficacy and selectivity. Mol Neurobiol. 36(1): 15-25.
62. Fride E (2008). Multiple Roles for the Endocannabinoid System During the Earliest Stages of Life: Pre- and Postnatal Development. J Neuroendocrinol. 20 (Suppl 1): 75-81.
63. Gamber KM, Macarthur H, Westfall TC (2005). Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. Neuropharmacology. 49(5): 646-652. (Pubitemid 41208286)
64. Gasperi V, Fezza F, Pasquariello N, Bari M et al (2007). Endocannabinoids in adipocytes during differentiation and their role in glucose uptake. Cell Mol Life Sci. 64(2): 219-229. (Pubitemid 46155701)
65. Gomez R, Navarro M, Ferrer B, Trigo JM et al (2002). A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 22(21): 9612-9617. (Pubitemid 35356203)
66. Gonthier MP, Hoareau L, Festy F, Matias I et al (2007). Identification of endocannabinoids and related compounds in human fat cells. Obesity. 15(4): 837-845. (Pubitemid 46740958)
67. Gosman G, Katcher H, LegroR (2006). Obesity and the role of gut and adipose hormones in female reproduction. Human Reproduction Update, 12(5): 585-601. (Pubitemid 44288711)
68. Grasemann C, Wessels HT, Knauer-Fischer S, Richter-Unruh A (2004). Increase of serum leptin after short-term pulsatile GnRH administration in children with delayed puberty. Eur J Endocrinol. 150(5): 691-698. (Pubitemid 38786540)
69. Grassi F, Quarti-Trevano G, Seravalle F, Arenare G et al (2008). Blood Pressure Lowering Effects of Rimonabant in Obesity-related Hypertension. J Neuroendocrinol. 20(Supp1): 63-68. (Pubitemid 351559283)
70. Grinspoom S, Gulick T, Askari H, Landt M et al, 1996. Serum leptin levels in women with anorexia nervosa. J Clin Endocrinol Metab. 81(11): 3861-3863. (Pubitemid 26380387)
71. Grisaru-Granovsky S, Samueloff A, Elstein D (2008). The role of leptin in fetal growth: a short review from conception to delivery. Eur J Obstet Gynecol Reprod Biol. 136(2): 146-150. (Pubitemid 351173461)
72. Guzman M, Lo Verme J, Fu J, Oveisi F, Blazquez C. et al (2004). Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha). J Biol Chem. 279(27): 27849-32754 (Pubitemid 38900052)
73. Guzman M (2003). Cannabinoids: potential anticancer agents. Nat Rev Cancer. 3(10): 745-755.
74. Hall W, Christie M, Currow D (2005). Cannabinoids and cancer: causation, remediation, and palliation. Lancet Oncol. 6(1): 35-42. (Pubitemid 40100410)
75. Hart S, Fischer OM, Ullrich A. 2004. Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. Cancer Res. 64(6): 1943-1950. (Pubitemid 38339438)
76. Hashimotodani Y, Ohno-Shosaku T, Kano M (2007). Endocannabinoids and synaptic function in the CNS. Neuroscientist. 13(2): 127-137. (Pubitemid 46524316)
77. Helliwell RJ, Chamley LW, Blake-Palmer K, Mitchell MD et al (2004). Characterization of the endocannabinoid system in early human pregnancy. J Clin Endocrinol Metab. 89(10): 5168-5174. (Pubitemid 39391465)
78. Henson MC, Castracane VD.2006. Leptin in pregnancy: an update. Biol Reprod. 74(2): 218-229.
79. Hentges ST, Low MJ, Williams JT (2005). Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci. 25(42): 9746-9751.
80. Hermann A, Kaczocha M, Deutsch DG. 2006. 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPS J. 8(2): E409-412. (Pubitemid 43964451)
81. Hiley CR, Kaup SS (2007). GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol. 152(5): 559-561.
82. Hill MN, Patel S, Carrier EJ, Rademacher DJ et al (2005). Down-regulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology. 30(3): 508-515. (Pubitemid 40271153)
83. Hill MN, Miller GE, HO WS, Gorzalka BB et al (2008). Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. Pharmacopsychiatry. 41(2): 48-53.
84. Hillard CJ. 2000. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat. 61(1-2): 3-18.
85. Ho WS, Hillard CJ (2005). Modulators of endocannabinoid enzymic hydrolysis and membrane transport. Handb Exp Pharmacol.168: 187-207.
86. Howlett AC, Breivogel CS, Childers SR, Deadwyler SA et al (2004). Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47: 345-358. (Pubitemid 39298276)
87. Izzo AA, Camilleri M (2008). Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut. 57(8): 1140-1155.
88. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I et al. 2005. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19(11): 1567-1569. (Pubitemid 41279033)
89. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I et al (2005). The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J. 19(11): 1567-1569. (Pubitemid 41279033)
90. Jellinger PS (2007). Metabolic consequences of hyperglycemia and insulin resistance. Clin Cornerstone. 8(Suppl 7): S30-42.
91. Jensen DP, Andreasen CH, Andersen MK, Hansen L et al (2007). The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J Mol Med. 85(5): 445-449. (Pubitemid 46701653)
92. Jesudason, D, Wittert G. 2008. Endocannabinoid system in food intake and metabolic regulation. Curr Opin Lipidol. 19(4): 344-348.
93. Jhaveri MD, Richardson D, Chapman V (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol. 152(5): 624-632. (Pubitemid 350034979)
94. Jonsson, K Holt S Fowler C (2006).The endocannabinoid system: current pharmacological research and therapeutic possibilities. Bas Clin Pharmacol Toxicol 98: 124-134.
95. Johnson RA, Vettor R, Rossato M, Fallo F, Pagano C (2007). The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from rimonabant in obesity (RIO) trials. Clin Cornerstone. 8(3): 82. (Pubitemid 351597787)
96. Juan-Pico P, Fuentes E, Bermudez-Silva FJ, Javier Diaz-Molina F et al (2006). Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell Calcium. 39(2): 155-162. (Pubitemid 43013847)
97. Kawada T, Goto T, Hirai S, Kang MS et al (2008). Dietary regulation of nuclear receptors in obesity-related metabolic syndrome. Asia Pac J Clin Nutr. 17(Suppl 1): 126-130.
98. Kawamura K, Sato N, Fukuda J, Kodama H et al (2003). Ghrelin inhibits the development of mouse preimplantation embryos in vitro. Endocrinology. 144(6): 2623-2633. (Pubitemid 36629915)
99. Kintscher U. 2008. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS. doi: 10.1093/eur-heartj/ehn255.
100. Kirkham TC, Williams CM. 2004.Endocannabinoid receptor antagonists: potential for obesity treatment. Treat Endocrinol. 3(6): 345-360. (Pubitemid 39546174)
101. Kofalvi A (2007). Cannabinoids and the Brain. Springer (eds).
102. Kong AP, Chan NN, Chan JC (2006). The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev. 2(4): 397-407. (Pubitemid 44734227)
103. Kuusisto J, Andrulionyte L, Laakso M. (2007). Atherosclerosis and cardiovascular risk reduction with PPAR agonists. Curr Atheroscler Rep. 9(4): 274-280. (Pubitemid 350081471)
104. Kyrou I, Valsamakis G, Tsigos C (2006). The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. Ann N Y Acad Sci. 1083: 270-305. (Pubitemid 44955478)
105. Labar G, Michaux C (2007). Fatty acid amide hydrolase: from characterization to therapeutics. Chem Biodivers. 4(8): 1882-1902. (Pubitemid 47377207)
106. Lafontan M, Piazza PV, Girard J (2007). Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab. 33(2): 85-95.
107. Laviolette SR, Grace AA (2006). The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci. 63(14): 1597-1613
108. Lenman A, Fowler CJ (2007). Interaction of ligands for the peroxisome proliferator-activated receptor gamma with the endocannabinoid system. Br J Pharmacol. 151(8): 1343-1351.
109. López-Moreno JA, González-Cuevas G, Moreno G, Navarro M (2008). The pharmacology of the endocannabinoid system: functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction. Addict Biol. 13(2): 160-187. (Pubitemid 351692981)
110. Lord E, Ledoux S, Murphy BD, Beaudry D et al (2005). Expression of adiponectin and its receptors in swine. J Anim Sci. 83(3): 565-578. (Pubitemid 43324065)
111. Loucks AB (2007). Energy availability and infertility. Curr Opin Endocrinol Diabetes Obes. 14(6): 470-474.
112. Maccarrone M, Falciglia K, Di Rienzo M, Finazzi-Agrò A. 2002. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukot Essent Fatty Acids. 66(2-3): 309-317. (Pubitemid 34743604)
113. Maccarrone M. Finazzi-Agró A (2003). The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis. Cell Death Differ. 10(9): 946-955. (Pubitemid 37069472)
114. Maccarrone M (2006). Fatty acid amide hydrolase: a potential target for next generation therapeutics. Curr Pharm Des. 12(6): 759-772.
115. Maccarrone M (2008). CB2 receptors in reproduction. Br J Pharmacol. 153(2): 189-198.
116. Mackie K (2008). Cananbinoid Receptors: where they are and what they do. J Neuroendocrinol. 20(1): 10-14. (Pubitemid 351552670)
117. Mackie K (2008). Signaling via CNS cannabinoid receptors. Mol Cell Endocrinol. 286(1-2 Suppl 1): S60-S65.
118. Mallat A, Lotersztajn S (2006). Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest. 29(3 Suppl): 58-65.
119. Martínez-Orgado J, Fernández-López D, Lizasoain I, Romero J (2007). The seek of neuroprotection: introducing cannabinoids. Recent Patents CNS Drug Discov 2(2): 131-139.
120. Massa F, Monory K (2006). Endocannabinoids and the gastrointestinal tract. J Endocrinol Invest. 29(3 Suppl): 47-57.
121. Matejek N, Weimann E, Witzel C, Mölenkamp G. 1999. Hypoleptinaemia in patients with anorexia nervosa and in elite gymnasts with anorexia athletica. Int J Sports Med. 20(7): 451-456. (Pubitemid 29488071)
122. Mathieu P, Pibarot P, Larose E, Poirier P, Marette A, Després JP (2008). Visceral obesity and the heart. Int J Biochem Cell Biol. 40(5): 821-836.
123. Matias I, Gonthier MP, Orlando P, Martiadis V et al (2006). Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 91(8): 3171-3180. (Pubitemid 44271774)
124. Matias I, Di Marzo V (2007). Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 18(1): 27-37.
125. Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R et al. 2007.Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol. 152(5): 676-690. (Pubitemid 350041540)
126. Matias I, Cristino L, Di Marzo V (2008). Endocannabinoids: some like it fat (and sweet too). J Neuroendocrinol. 20(1): 100-109. (Pubitemid 351552684)
127. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA et al (2008). Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol. 286(1-2 Suppl 1): S66-78.
128. Matias I, Vergoni AV, Petrosino S, Ottani A et al (2008). Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: insulin and melanocortins. Neuropharmacology. 54(1): 206-212. (Pubitemid 350299405)
129. Matkovic V, Ilich JZ, Skugor M, Badenhop Ne et al (1997). Leptin is inversely related to age at menarche in human females.J Clin Endocrinol Metab. 82(10): 3239-3245.
130. Mazaki-Tovi S, Kanety H, Sivan E (2005). Adiponectin and human pregnancy.Curr Diab Rep. 5(4): 278-281.
131. Metwally M, Li TC, Ledger WL (2007). The impact of obesity on female reproductive function. Obes Rev. 8(6): 515-1253 (Pubitemid 47620724)
132. Mircea CN, Lujan ME, Pierson RA. 2007. Metabolic fuel and clinical implications for female reproduction. J Obstet Gynaecol Can. 29(11): 887-902.
133. Mitchell M, Armstrong DT, Robker RL, Norman RJ (2005). Adipokines: implications for female fertility and obesity. Reproduction. 130(5): 583-597. (Pubitemid 41646045)
134. Mitchell PB, Morris MJ (2007). Depression and anxiety with rimonabant. Lancet. 370 (9600): 1671-1672.
135. Monteleone P, Matias i, Martiadis V, DePetrocellis L etal (2005). Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 30(6): 1216-1221.
136. Moreira FA, Lutz B (2008). The endocannabinoid system: emotion, learning and addiction. Addict Biol. 13(2): 196-212.
137. Müller-Vahl KR, Emrich HM (2008). Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 8(7): 1037-1048.
138. Nakada M, Yada T (2008). Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept. 145(1-3): 49-53.
139. Nieswandt B, Aktas B, Moers A, Sachs UJ (2005). Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost. 3(8): 1725-1736. (Pubitemid 41716559)
140. Nishizawa H, Shimomura I, Kishhida K, Maeda N et al (2002). Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 51(9): 2734-2741. (Pubitemid 34970926)
141. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J et al (2008). Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 299(13): 1547-1560
142. Nixon PJ (2006). Health effects of marijuana: a review. Pac Health Dialog. 13(2): 123-129.
143. Ofek O, Karsak M, Leclerc N, Fogel M et al (2006). Peripheral can-nabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA. 103(3): 696-701. (Pubitemid 43153088)
144. Onaivi E., Sugiura T., Di Marzo V (2006). Endocannabinoids. The Brain and Body's marijuana and beyond. CRC Press. Taylor and Francis Group (eds).
145. Orio F, Palomba S, Cascella T, Milan G et al (2003). Adiponectin levels in women with polycystic ovary syndrome.J Clin Endocrinol Metab. 88(6): 2619-2623.
146. Osei-Hyiaman D, DePetrillo M, Patcher P, Liu J et al (2005). Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest. 115(5): 1298-1305. (Pubitemid 40629049)
147. Osei-Hyiaman D, Harvey-White J, Bátkai S, Kunos G (2006).The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes. 30 (Suppl.1): S33-S38.
148. O'Sullivan SE (2007). Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol. 152(5): 576-582. (Pubitemid 350034977)
149. Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L et al (2005). Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol. 289(2): H533-541. (Pubitemid 41129366)
150. Pacher P, Bátkai S, Kunos G (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58(3): 389-462. (Pubitemid 44394908)
151. Pagano C, Pilon C, Calcagno A, Urbanet R. et al (2007). The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab. 92(12): 4810-4819.
152. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R (2006).The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 27(1): 73-100. (Pubitemid 43228239)
153. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G (2003). Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod. 18(9): 1790-1796. (Pubitemid 37107549)
154. Paradisi A, Oddi S, Maccarrone M (2006).The endocannabinoid system in ageing: a new target for drug development. Curr Drug Targets. 7(11): 1539-1552. (Pubitemid 44718311)
155. Paraskevas KI, Liapis CD, Mikkhailidis DP (2006). Leptin: a promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets. 7(6): 761-771.
156. Paria BC, Das SK, Dey SK (1995). The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc Natl Acad Sci U S A. 92(21): 9460-9464.
157. Paria BC, Deutsch DD, Dey SK (1996). The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol Reprod Dev. 45(2): 183-192.
158. Paria BC, Zhao X, Wang J, Das SK, Dey SK (1999). Fatty-acid amide hydrolase is expressed in the mouse uterus and embryo during the periimplantation period. Biol Reprod. 60(5): 1151-1157. (Pubitemid 29196767)
159. Paria BC, Dey SK (2000). Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids 108(1-2): 211-220.
160. Paria BC, Wang H, Dey SK (2002). Endocannabinoid signaling in synchronizing embryo development and uterine receptivity for implantation. Chem Phys Lipids. 12(1-2): 201-210. (Pubitemid 36044552)
161. Park B, McPartland JM, Glass M (2004). Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fatty Acids. 70(2): 189-197.
162. Pasquali R, Gambineri A, Pagotto U (2006). The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 113(10): 1148-1159. (Pubitemid 44401208)
163. Pasquali R, Gambineri A (2006). Metabolic effects of obesity on reproduction. Reprod Biomed Online. 12(5): 542-551.
164. Patcher P, Batkai S, Kunos G (2005). Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology. 48: 1130-1138. (Pubitemid 40725985)
165. Perez LE, Smith CG, Asch RH (1981). A9-tetrahydrocannabinol inhibits fructose utilization and motility in human, rhesus monkey, and rabbit sperm in vitro. Fertil Steril. 35(6): 703-705.
166. Pertwee RG (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol.168: 1-51.
167. Pertwee RG (2006). The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes. 30 (Suppl 1): S13-8.
168. Pertwee RG (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 152(7): 984-986.
169. Pertwee RG. 2008. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 13(2): 147-159.
170. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol.153(2): 199-215.
171. Petersen G, Sorensen C, Schmid PC, Artmann A et al (2006). Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta. 1761(2): 143-150.
172. Piomelli D (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs. 6(7): 672-679.
173. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J et al (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 295(7): 761-775 (Pubitemid 43244304)
174. Poso A, Huffman JW (2008). Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.Br J Pharmacol. 153(2): 335-346.
175. Prostaglandins Other Lipid Mediat. 83(1-2): 62-74.
176. Puffenbarger RA (2005). Molecular biology of the enzymes that degrade endocannabinoids. Curr Drug Targets CNS Neurol Disord. 4(6): 625-631. (Pubitemid 41782624)
177. Pushkarev VM, Kovzun OI, Tronko MD (2008). Antineoplastic and apoptotic effects of cannabinoids. N-acylethanolamines: protectors or killers? Exp Oncol. 30(1): 6-21.
178. Randall MD (2007). Endocannabinoids and the haematological system. Br J Pharmacol. 152(5): 671-675.
179. Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrié P (2004). CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord. 28(4): 640-648.
180. Reggio PH (2005). Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches. Handb Exp Pharmacol. 168: 247-281.
181. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP et al. 2006. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol. 126(2): 177-187.
182. Rossato M (2008). Endocannabinoids, sperm functions and energy metabolism. Mol Cell Endocrinol. 286(1-2 Suppl 1): S31-S35.
183. Rossato M., C. Pagano, R. Vettor (2008). The Cannabinoid System and Male Reproductive Functions. J Neuroendocrinol. 20 (Suppl 1): 90-93. (Pubitemid 351552682)
184. Russo P, Strazzullo P, Cappuccio FP, Tregouet DA et al (2007). Genetic variations at the endocannabinoid type 1 receptor gene (CNR1) are associated with obesity phenotypes in men. J Clin Endocrinol Metab. 92(6): 2382-2386. (Pubitemid 46997151)
185. Saario SM, Laitinen JT (2007). Monoglyceride lipase as an enzyme hydrolyzing 2-arachidonoylglycerol. Chem Biodivers. 4(8): 1903-1913.
186. Saario SM, Laitinen JT (2007). Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. Basic Clin Pharmacol Toxicol. 101(5): 287-293. (Pubitemid 47512389)
187. Sarfaraz S, Adhami VM, Syed DN, Afaq F et al (2008). Cannabinoids for cancer treatment: progress and promise. Cancer Res. 68(2): 339-342.
188. Sarzani R (2008). Endocannabinoids, Blood Pressure and the Human Heart. J Neuroendocrinol. 20(Supp1): 59-62.
189. Scheen AJ, Finer N, Hollander P, Jensen MD et al (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 368(9548): 1660-1672 (Pubitemid 46048528)
190. Scheen AJ. 2008. CB1 receptor blockade and its impact on car-diometabolic risk factors: overview of the RIO programme withrimonabant. J Neuroendocrinol. 20 (Suppl 1): 139-146
191. Schuel H, Burkman LJ, Lippes J, Crickard K et al (2002). N-Acylethanolamines in human reproductive fluids. Chem Phys Lipids. 121(1-2): 211-227. (Pubitemid 36044553)
192. Siegmund SV, Schwabe RF (2008). Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 294(2): G357-362.
193. Sipe JC, Waalen J, Gerber A, Beutler E (2005). Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes 29(7): 755-759. (Pubitemid 40897010)
194. Smita K, Kumar SV, Premendran JS (2007). Anandamide: an update. Fundam Clin Pharmacol. 21(1): 1-8.
195. Starowicz KM, Cristino L, Matias I, Capasso R Racioppi A et al (2008). Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity. 16(3): 553-565. (Pubitemid 351328005)
196. Steffens S, Veillard NR, Arnaud C, Pelli G et al (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 434(7034): 782-786. (Pubitemid 44739523)
197. Stein EA, Fuller SA, Edgemond WS, Campbell WB (1996). Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br J Pharmacol. 119(1): 107-114.
198. Stern E, Lambert DM (2007). Medicinal chemistry endeavors around the phytocannabinoids. Chem Biodivers. 4(8): 1707-1728. (Pubitemid 47381193)
199. Storr MA, Keeman CM, Emmerdinger D, Zhang H et al (2008). Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB(1) and CB (2) receptors. J Mol Med. In press.
200. Strobel A, Issad T, Camoin L, Ozata M, Strosberg AD (1998). A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet. 18(3): 213-215.
201. Sun Y, Alexander SP, Garle MJ, Gibson CL et al (2007).Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 152(5): 734-743.
202. Sun X, Dey SK (2008). Aspects of endocannabinoid signaling in periimplantation biology. Mol Cell Endocrinol. 286(1-2 Suppl 1): S3-S11.
203. Tam J, Ofek O, Fride E, Ledent C, Gabet Y et al. (2006). Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol. 70(3): 786-792. (Pubitemid 44268435)
204. Tam J, Trmbovler V, DiMarzo V, Petrosino S et al (2008). The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J. 22(1): 285-294.
205. Taylor AH, Ang C, Bell SC, Konje JC (2007). The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. Hum Reprod Update. 13(5): 501-513. (Pubitemid 47299855)
206. Tyler K, Hillard CJ, Greenwood-Van Meerveld B (2000). Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. Eur J Pharmacol. 409(2): 207-211. (Pubitemid 30947053)
207. Valassi E, Scacchi M, Cavagnini F (2008). Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis.18(2): 158-168. (Pubitemid 351282471)
208. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, et al (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 365(9468): 1389-1397 (Pubitemid 40523733)
209. Vandevoorde S (2008). Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors. Curr Top Med Chem. 8(3): 247-267.
210. Vaughan CW, Christie MJ (2005). Retrograde signalling by endocannabinoids. Handb Exp Pharmacol. 168: 367-383.
211. Velasco G, Carracedo A, Blazquez C, Lorente M et al (2007). Cannabinoids and gliomas. Mol Neurobiol. 36(1): 60-67.
212. Verty AN, McFarlane JR, McGregor IS, Mallet PE (2004). Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology. 145(7): 3224-3231. (Pubitemid 38829994)
213. Vignesh JP, Mohan V (2007). Polycystic ovary syndrome: a component of metabolic syndrome?J Postgrad Med. 53(2): 128-134.
214. Vinod K, Arango V, Xie S, Kassir SA et al (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry. 57(5): 480-486. (Pubitemid 40311982)
215. Vinod KY, Hungund BL (2005). Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatrie disorders. Life Sci. 77(14): 1569-1583.
216. Vinod KY, Hungund BL (2006). Role of the endocannabinoid system in depression and suicide.Trends Pharmacol Sci. 27(10): 539-545.
217. Viso A, Cisneros JA, Ortega-Gutiérrez S (2008). The medicinal chemistry of agents targeting monoacylglycerol lipase. Curr Top Med Chem. 8(3): 231-246. (Pubitemid 351795771)
218. Wang H, Dey SK, Maccarrone M (2006). Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. Endocr Rev. 27(5): 427-448. (Pubitemid 44213226)
219. Wang H, Xie H, Sun X, Kingsley PJ et al (2007). Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation. 83(1-2): 62-74.
220. Wang J, Natsuo U (2007). Role of the endocannabinoid system in metabolic control. Curr Opin Nephrol Hypertens. 17(1): 1-10.
221. Watanabe S, Doshi M, Hamazaki T (2003). n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins Leukot Essent Fatty Acids. 69(1): 51-59. (Pubitemid 37421501)
222. Woelkart K, Salo-Ahen OM, Bauer R (2008). CB receptor ligands from plants. Curr Top Med Chem 8(3): 173-186.
223. Wolf SA, Ullrich O (2008). Endocannabinoids and the Brain Immune System: New Neurones at the Horizon? J Neuroendocrinol. 20 (Suppl 1): 15-19.
224. Wright KL, Duncan M, Sharkey KA (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 153(2): 263-270.
225. Xie S, Furjanic MA, Ferrara JJ, McAndrew NR et al (2007). The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use J Clin Pharm Therap 32: 209-231.
226. Yan ZC, Liu DY, Zhang LL, Shen CY et al (2007). Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun. 354(2): 427-433.
227. Zhao LJ, Jiang H, Papasian CJ, Maulik D et al (2008). Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res. 23(1): 17-29.